BR112012022064A2 - tratamento de artrite lúpica usando laquinimod - Google Patents

tratamento de artrite lúpica usando laquinimod

Info

Publication number
BR112012022064A2
BR112012022064A2 BR112012022064A BR112012022064A BR112012022064A2 BR 112012022064 A2 BR112012022064 A2 BR 112012022064A2 BR 112012022064 A BR112012022064 A BR 112012022064A BR 112012022064 A BR112012022064 A BR 112012022064A BR 112012022064 A2 BR112012022064 A2 BR 112012022064A2
Authority
BR
Brazil
Prior art keywords
laquinimod
lupus arthritis
treatment
treating
pharmaceutically acceptable
Prior art date
Application number
BR112012022064A
Other languages
English (en)
Inventor
Asi Haviv
Nora Tarcic
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531530&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012022064(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112012022064A2 publication Critical patent/BR112012022064A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

tratamento de artrite lúpica usando laquinimod esta invenção fornece um método de tratamento de um sujeito afetado com artrite lúpica ativa compreendendo periodicamente a administração à pessoa de uma quantidade de laquinimod ou sal farmaceuticamente aceitável do mesmo, eficaz para tratar o sujeito. esta invenção também proporciona o laquinimod ou sal farmaceuticamente aceitável do mesmo, para utilização no tratamento de um sujeito afetado com artrite lúpica ativa. essa invenção proporciona ainda uma composição farmacêutica compreendendo uma quantidade de laquinimod ou sal farmaceuticamente aceitável do mesmo, para utilização no tratamento de um sujeito afetado com artrite lúpica.
BR112012022064A 2010-03-03 2011-03-02 tratamento de artrite lúpica usando laquinimod BR112012022064A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33935510P 2010-03-03 2010-03-03
PCT/US2011/026891 WO2011109536A1 (en) 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod

Publications (1)

Publication Number Publication Date
BR112012022064A2 true BR112012022064A2 (pt) 2015-09-08

Family

ID=44531530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022064A BR112012022064A2 (pt) 2010-03-03 2011-03-02 tratamento de artrite lúpica usando laquinimod

Country Status (21)

Country Link
US (4) US20110217295A1 (pt)
EP (1) EP2542080B1 (pt)
JP (2) JP2013521305A (pt)
KR (1) KR20130036217A (pt)
CN (1) CN102781239B (pt)
AU (1) AU2011223702B2 (pt)
BR (1) BR112012022064A2 (pt)
CA (1) CA2791711A1 (pt)
CL (1) CL2012002422A1 (pt)
CO (1) CO6630086A2 (pt)
EA (1) EA201290859A1 (pt)
ES (1) ES2601819T3 (pt)
HK (1) HK1177876A1 (pt)
MX (1) MX342001B (pt)
NZ (1) NZ602512A (pt)
PE (1) PE20130496A1 (pt)
PL (1) PL2542080T3 (pt)
PT (1) PT2542080T (pt)
SG (2) SG10201501539SA (pt)
WO (1) WO2011109536A1 (pt)
ZA (1) ZA201207125B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101440982B1 (ko) * 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
ES2377149T3 (es) 2006-06-12 2012-03-22 Teva Pharmaceutical Industries Limited Preparaciones de laquinimod estables
EP2977049A1 (en) 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
CN104311486A (zh) * 2008-09-03 2015-01-28 泰华制药工业有限公司 2-羰基-1,2-二氢喹啉免疫功能调节剂
RS54328B1 (en) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
SI2467372T1 (sl) 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
CN102781239B (zh) * 2010-03-03 2015-01-21 泰华制药工业有限公司 使用拉喹莫德治疗狼疮关节炎
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
KR20160129093A (ko) * 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
JP2013535437A (ja) 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
BR112014018485A8 (pt) 2012-02-03 2017-07-11 Teva Pharma Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013341506A1 (en) 2012-11-07 2015-06-04 Teva Pharmaceutical Industries Ltd. Amine salts of Laquinimod
SG11201506409RA (en) 2013-03-14 2015-09-29 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EP2968203A1 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
CN106573014A (zh) 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
CN100390148C (zh) * 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
JP2007526230A (ja) * 2003-06-25 2007-09-13 エラン ファーマシューティカルズ，インコーポレイテッド 関節リウマチを治療する方法および組成物
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2005097162A2 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2007142667A2 (en) * 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
KR101440982B1 (ko) * 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
CA2623879C (en) * 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
HUE047230T2 (hu) * 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
EP1991267B1 (en) * 2006-03-03 2017-12-20 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) * 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
ES2377149T3 (es) * 2006-06-12 2012-03-22 Teva Pharmaceutical Industries Limited Preparaciones de laquinimod estables
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
BRPI0814624A2 (pt) * 2007-07-11 2015-01-27 Medicinova Inc Tratamento de doença neurodegenerativa progresiva com ibudilaste
EP2977049A1 (en) * 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
CN104311486A (zh) * 2008-09-03 2015-01-28 泰华制药工业有限公司 2-羰基-1,2-二氢喹啉免疫功能调节剂
RS54328B1 (en) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
SI2467372T1 (sl) * 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
CN102781239B (zh) * 2010-03-03 2015-01-21 泰华制药工业有限公司 使用拉喹莫德治疗狼疮关节炎
JP2013535437A (ja) * 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
SG11201506409RA (en) * 2013-03-14 2015-09-29 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof

Also Published As

Publication number Publication date
US20130184310A1 (en) 2013-07-18
ZA201207125B (en) 2014-06-25
EP2542080B1 (en) 2016-08-31
US20150086549A1 (en) 2015-03-26
CL2012002422A1 (es) 2012-12-21
SG10201501539SA (en) 2015-04-29
AU2011223702B2 (en) 2016-07-14
PE20130496A1 (es) 2013-05-08
CN102781239A (zh) 2012-11-14
CN102781239B (zh) 2015-01-21
MX2012010071A (es) 2012-10-03
MX342001B (es) 2016-09-09
CO6630086A2 (es) 2013-03-01
CA2791711A1 (en) 2011-09-09
AU2011223702A1 (en) 2012-10-25
NZ602512A (en) 2014-07-25
JP2013521305A (ja) 2013-06-10
EA201290859A1 (ru) 2013-04-30
EP2542080A4 (en) 2013-07-17
PT2542080T (pt) 2016-11-16
PL2542080T3 (pl) 2017-02-28
JP2016196473A (ja) 2016-11-24
HK1177876A1 (zh) 2013-08-30
ES2601819T3 (es) 2017-02-16
KR20130036217A (ko) 2013-04-11
EP2542080A1 (en) 2013-01-09
US20160213663A1 (en) 2016-07-28
WO2011109536A1 (en) 2011-09-09
US20110217295A1 (en) 2011-09-08
SG183515A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
BR112012022064A2 (pt) tratamento de artrite lúpica usando laquinimod
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112012022187A2 (pt) tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BR112015006341A2 (pt) compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica
IN2015DN03219A (pt)
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX365427B (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
BR112012020060A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero.
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]